Citigroup’s Enzo Biochem, Inc. ENZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-78
| Closed | – | – | 6380 |
|
|
2021
Q2 | $0 | Sell |
78
-2,862
| -97% | -$9K | ﹤0.01% | 6454 |
|
|
2021
Q1 | $10K | Sell |
2,940
-5,427
| -65% | -$16.9K | ﹤0.01% | 5663 |
|
|
2020
Q4 | $21K | Buy |
8,367
+6,233
| +292% | +$13.6K | ﹤0.01% | 6622 |
|
|
2020
Q3 | $5K | Sell |
2,134
-3,689
| -63% | -$8.77K | ﹤0.01% | 7055 |
|
|
2020
Q2 | $13K | Sell |
5,823
-6,494
| -53% | -$16.7K | ﹤0.01% | 6926 |
|
|
2020
Q1 | $31K | Buy |
12,317
+3,287
| +36% | +$8.07K | ﹤0.01% | 6390 |
|
|
2019
Q4 | $24K | Buy |
9,030
+1,111
| +14% | +$3.32K | ﹤0.01% | 6856 |
|
|
2019
Q3 | $29K | Sell |
7,919
-3,351
| -30% | -$11.9K | ﹤0.01% | 6512 |
|
|
2019
Q2 | $38K | Sell |
11,270
-815
| -7% | -$2.87K | ﹤0.01% | 6712 |
|
|
2019
Q1 | $33K | Buy |
12,085
+530
| +5% | +$1.74K | ﹤0.01% | 6675 |
|
|
2018
Q4 | $32K | Sell |
11,555
-1,076
| -9% | -$3.52K | ﹤0.01% | 6587 |
|
|
2018
Q3 | $52K | Buy |
12,631
+4,653
| +58% | +$21.1K | ﹤0.01% | 6497 |
|
|
2018
Q2 | $41K | Sell |
7,978
-8,769
| -52% | -$53.4K | ﹤0.01% | 6438 |
|
|
2018
Q1 | $92K | Buy |
16,747
+6,876
| +70% | +$48.4K | ﹤0.01% | 5689 |
|
|
2017
Q4 | $81K | Sell |
9,871
-1,270
| -11% | -$12.1K | ﹤0.01% | 5832 |
|
|
2017
Q3 | $116K | Buy |
11,141
+6,684
| +150% | +$74.2K | ﹤0.01% | 5448 |
|
|
2017
Q2 | $49K | Sell |
4,457
-2,142
| -32% | -$20K | ﹤0.01% | 5810 |
|
|
2017
Q1 | $55K | Sell |
6,599
-34,296
| -84% | -$242K | ﹤0.01% | 5631 |
|
|
2016
Q4 | $284K | Buy |
40,895
+16,630
| +69% | +$106K | ﹤0.01% | 4985 |
|
|
2016
Q3 | $124K | Buy |
24,265
+17,418
| +254% | +$104K | ﹤0.01% | 5050 |
|
|
2016
Q2 | $41K | Sell |
6,847
-1,242
| -15% | -$6.89K | ﹤0.01% | 5694 |
|
|
2016
Q1 | $37K | Buy |
8,089
+5,939
| +276% | +$26.4K | ﹤0.01% | 6263 |
|
|
2015
Q4 | $10K | Sell |
2,150
-142
| -6% | -$600 | ﹤0.01% | 6824 |
|
|
2015
Q3 | $7K | Sell |
2,292
-192
| -8% | -$583 | ﹤0.01% | 6613 |
|
|
2015
Q2 | $8K | Buy |
2,484
+384
| +18% | +$1.08K | ﹤0.01% | 6582 |
|
|
2015
Q1 | $6K | Sell |
2,100
-4,113
| -66% | -$13.5K | ﹤0.01% | 6672 |
|
|
2014
Q4 | $27K | Buy |
6,213
+4,974
| +401% | +$23.7K | ﹤0.01% | 6074 |
|
|
2014
Q3 | $6K | Buy |
1,239
+900
| +265% | +$4.8K | ﹤0.01% | 6509 |
|
|
2014
Q2 | $2K | Buy |
339
+319
| +1,595% | +$1.38K | ﹤0.01% | 6784 |
|
|
2014
Q1 | $0 | Sell |
20
-77
| -79% | -$264 | ﹤0.01% | 7238 |
|
|
2013
Q4 | $0 | Buy |
97
+77
| +385% | +$191 | ﹤0.01% | 7183 |
|
|
2013
Q3 | $0 | Hold |
20
| – | – | ﹤0.01% | 7027 |
|
|
2013
Q2 | $0 | Buy |
+20
| New | +$44 | ﹤0.01% | 6803 |
|
Other funds holding ENZ
HFA
RAM
EGA
VCA
Citigroup's ENZ Position: Q3 2021 in Review
Citigroup sold out of Enzo Biochem, Inc. (ENZ) in Q3 2021, closing a stake of 78 shares.
Citigroup first reported a position in ENZ in Q2 2013 and held it in 33 quarters. The position peaked at $284K in Q4 2016. 65 funds tracked by Wall St. Rank hold ENZ as of Q3 2021.
- Citigroup reported no remaining Enzo Biochem, Inc. position as of Q3 2021 after selling out during the quarter.
- Citigroup sold 78 Enzo Biochem, Inc. shares in Q3 2021.
- Citigroup first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 33 quarters.
- Citigroup's Enzo Biochem, Inc. position peaked at $284K in Q4 2016.
- 65 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q3 2021.
Based on Citigroup's 13F filing for Q3 2021, filed 10 Nov 2021.